Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 18/20 | 1.00 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.53 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.53 |
| ▸ | CTSG | P08311 | 1/20 | 0.53 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL999162 | 1.00 | CMA1 (1.00) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL999159 | 1.00 | CMA1 (1.00) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL998999 | 0.93 | CMA1 (0.87) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL998997 | 0.93 | CMA1 (0.87) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL998241 | 0.92 | CMA1 (1.00) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL998237 | 0.92 | CMA1 (1.00) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL3653115 | 0.91 | CMA1 (1.00) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL3653104 | 0.91 | CMA1 (1.00) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| Choline SCHEMBL4371340 | 0.91 | CMA1 (0.82) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| Choline SCHEMBL4371344 | 0.91 | CMA1 (0.82) | CMA1PRSS1PRSS2CTSGPRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090169475-A1 | RADIOLABELED DERIVATIVES OF POTENT CHYMASE INHIBITORS | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090169475-A1 | RADIOLABELED DERIVATIVES OF POTENT CHYMASE INHIBITORS | CMA1, CPA3, CPA1 | CMA1 1/4885PRSS1 54/4885PRSS2 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.